AKCA Insider Trading Activity and SEC Form 4 Filings
AKCA insider trading summary
No open-market insider purchases or sales of Akcea Therapeutics, Inc. (AKCA) have been reported on SEC Form 4 in the past 12 months.
Latest AKCA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 10, 2020 | Ionis Pharmaceuticals Inc | 10% Owner | Buy | $385.5M (21,237,715 @ $18.15) |
| Sep 22, 2020 | Kyle Jenne | Chief Commercial Officer | Sell | $13K (720 @ $18.12) |
| Sep 22, 2020 | Joshua F. Patterson | General Counsel | Sell | $6K (319 @ $18.12) |
| Sep 22, 2020 | Damien McDevitt | Chief Executive Officer | Sell | $158K (8,709 @ $18.12) |
| Jul 17, 2020 | Joshua F. Patterson | General Counsel | Sell | $3K (263 @ $12.50) |
| Mar 23, 2020 | Kyle Jenne | Chief Commercial Officer | Sell | $9K (779 @ $11.75) |
| Mar 23, 2020 | Louis O'Dea | Chief Medical Officer | Sell | $38K (3,198 @ $11.75) |
| Mar 23, 2020 | Joshua F. Patterson | General Counsel | Sell | $4K (335 @ $11.76) |
| Mar 23, 2020 | Damien McDevitt | Chief Executive Officer | Sell | $111K (9,417 @ $11.75) |
| Jul 15, 2019 | Sarah Boyce | President | Sell | $43K (1,819 @ $23.52) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.